STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2020

Jan 24, 2020

January 24, 2020

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531

The National Stock Exchange of India Limited Exchange Plaza , Bandra‐Kurla Complex Bandra (E) Mumbai ‐ 400 051 Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

‘Strides receives USFDA tentative approval for Triamcinolone Acetonide Ointment’

Thanks & Regards,

For Strides Pharma Science Limited

==> picture [127 x 51] intentionally omitted <==

==> picture [106 x 26] intentionally omitted <==

----- Start of picture text ----- Manjula RamamurthyCompany Secretary----- End of picture text -----

==> picture [85 x 83] intentionally omitted <==

==> picture [70 x 8] intentionally omitted <==

----- Start of picture text ----- Encl: As Above----- End of picture text -----

Strides Pharma Science Limited

(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com

Press Release January 24, 2020

Strides receives USFDA tentative approval for Triamcinolone Acetonide Ointment

Product approval from flagship facility in Bangalore

To be marketed by Strides Pharma Inc. effective May 30,2020

Bangalore, January 24, 2020 ‐ Strides Pharma Science Limited (Strides) today announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received tentative approval for Triamcinolone Acetonide Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA).

While it was amongst the few Competitive Generic Therapy (CGT) designated products for Strides, another generic company received approval prior to our approval. Consequently, the final approval for Strides will be effective 30 May 2020 when the company will launch the product.

According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately US$ 20 Mn. The product will be manufactured at the company’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.

The company has 102 cumulative ANDA filings with USFDA of which 69 ANDAs have been approved and 33 are pending approval.

About Triamcinolone Acetonide Ointment

Triamcinolone Acetonide Ointment is in a class of medications called corticosteroids. It is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor‐funded markets. The Company’s global manufacturing sites are located in India‐ Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy‐ Milan, Kenya‐ Nairobi and United States‐Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

Strides PR Consultancy Badree Komandur Fortuna PR Executive Director ‐ Finance K Srinivas Reddy: +91 90005 27213 +91 80 6784 0747 srinivas@fortunapr.com Investor Relations: K Priya: +91 95354 25418 Kannan. N: +91 98450 54745 priya@fortunapr.com Vikesh Kumar: +91 80 6784 0827 Sandeep Baid: +91 80 6784 0791 Email: Sandeep.baid@strides.com Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Regd. Office: 201, ‘Devavrata’, Sector ‐ 17, Vashi, Navi Mumbai ‐ 400 703 Corp. Office: Strides House, Bannerghatta Road, Bangalore – 560 076